Results 11 to 20 of about 105,814 (267)

Atorvastatin Inhibits Inflammatory Response, Attenuates Lipid Deposition, and Improves the Stability of Vulnerable Atherosclerotic Plaques by Modulating Autophagy

Frontiers in Pharmacology, 2018
Atherosclerosis is a chronic disease comprising intima malfunction and arterial inflammation. Recent studies have demonstrated that autophagy could inhibit inflammatory response in atherosclerosis and exert subsequent atheroprotective effects.
Shi Peng, Long-Wei Xu, Xin-Yu Che, Qing-Qing Xiao, Jun Pu, Qin Shao, Ben He   +6 more
doaj   +2 more sources

Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial

British medical journal, 2023
Objective To compare the long term efficacy and safety of rosuvastatin with atorvastatin treatment in adults with coronary artery disease. Design Randomised, open label, multicentre trial.
Yong-Joon Lee, Sung‐Jin Hong, W. Kang, B. Hong, Jong-Young Lee, Jin-Bae Lee, Hyung-Jin Cho, Junghan Yoon, Seung-Jun Lee, C. Ahn, Jung‐Sun Kim, Byeong‐Keuk Kim, Y. Ko, D. Choi, Y. Jang, Meyong-Ki Hong   +15 more
semanticscholar   +1 more source

Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis

Frontiers in Cell and Developmental Biology, 2022
As one of the cornerstones of clinical cardiovascular disease treatment, statins have an extensive range of applications. However, statins commonly used have side reactions, especially muscle-related symptoms (SAMS), such as muscle weakness, pain, cramps,
Qi Zhang, H. Qu, Yinghui Chen, Xueyang Luo, Chong Chen, Bing Xiao, X-Z Ding, P. Zhao, Yanan Lu, Alex F. Chen, Yu Yu   +10 more
semanticscholar   +1 more source

Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial

British medical journal, 2022
Objective To assess the effect of statin treatment versus placebo on clinical outcomes in patients with covid-19 admitted to the intensive care unit (ICU).
P. Sadeghipour, B. Bikdeli, Azita H Talasaz, B. Sharif-Kashani, F. Rashidi, M. Beigmohammadi, K. G. Moghadam, Somayeh Rezaian, Seyed Ali Dabbagh, H. Sezavar, Mohsen Farrokhpour, H. Bakhshandeh, Atefeh Abedini, Rasoul Aliannejad, Mahdi Taghi Riahi, Somayeh Lookzadeh, P. Rezaeifar, S. Matin, Ouria Tahamtan, Keyhan Mohammadi, E. Zoghi, Seyed Hamid Rahmani, Hossein Hosseini Seyed, Masoud Mousavian, Homa Abri, Elahe Baghizadeh, F. Rafiee, Sepehr Jamalkhani, Ahmad Amin, Seyed Bahram Mohebbi, E. Parhizgar, Mahshid Soleimanzadeh, Maryam Aghakouchakzadeh, Vahid Eslami, P. Payandemehr, Hossein Khalili, H. Talakoob, Taranom Tojari, S. Shafaghi, Samrand Fattah, Sanaz Ghazi, Hessam Tabrizi, Alireza Kakavand, Kashefizadeh Shaghayegh, Atabak Shahmirzaei, M. Najafi, David Fathi, Aakriti Jimenez, Mahesh V Gupta, Sanjum S Madhavan, Sahil Sethi, Manuel Parikh, Naser Monreal, Alireza Hadavand, Hajighasemi Khalil, Majid Ansarin, Saeed Maleki, Gregory Sadeghian, Ajay J Piazza, Benjamin W Kirtane, Gregg W Van Tassell, Gregory Y H Stone, M. LipHarlan, Samuel Z Krumholz, Parham Sadeghipour Goldhaber   +64 more
semanticscholar   +1 more source

Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases

Cardiovascular Diabetology, 2022
Background Statin treatment increases the risk of new-onset diabetes mellitus (NODM); however, data directly comparing the risk of NODM among individual statins is limited. We compared the risk of NODM between patients using pitavastatin and atorvastatin
W. Seo, S. Seo, Yerim Kim, J. J. Yoo, W. Shin, Jinseob Kim, S. You, Rae Woong Park, Young Min Park, Kyung-Jin Kim, S. Rhee, Meeyoung Park, E. Jin, Sung Eun Kim   +13 more
semanticscholar   +1 more source

Atorvastatin is associated with reduced cisplatin-induced hearing loss.

Journal of Clinical Investigation, 2021
BACKGROUNDCisplatin is widely used to treat adult and pediatric cancers. It is the most ototoxic drug in clinical use, resulting in permanent hearing loss in approximately 50% of treated patients.
K. Fernandez, Paul D Allen, Marnie L Campbell, B. Page, Thomas G Townes, Chuanlin Li, Hui Cheng, J. Garrett, M. Mulquin, A. Clements, D. Mulford, Candice E Ortiz, C. Brewer, J. Dubno, Shawn Newlands, N. Schmitt, L. Cunningham   +16 more
semanticscholar   +1 more source

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial

RMD Open, 2021
Objectives Persons at high risk of rheumatoid arthritis (RA) might benefit from a low-risk pharmacological intervention aimed at primary prevention. Previous studies demonstrated disease-modifying effects of statins in patients with RA as well as an ...
L. van Boheemen, S. Turk, M. Beers-Tas, W. Bos, D. Marsman, E. Griep, M. Starmans-Kool, C. Popa, A. V. van Sijl, M. Boers, M. Nurmohamed, D. van Schaardenburg   +11 more
semanticscholar   +1 more source

ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury

Theranostics, 2020
Acute kidney injury (AKI) caused by sepsis is a serious disease which mitochondrial oxidative stress and inflammatory play a key role in its pathophysiology. Ceria nanoparticles hold strong and recyclable reactive oxygen species (ROS)-scavenging activity,
Hui Yu, Feiyang Jin, Di Liu, Gaofeng Shu, Xiaojuan Wang, Jing Qi, Min-cheng Sun, Ping Yang, Saiping Jiang, Xiaoying Ying, Yongzhong Du   +10 more
semanticscholar   +1 more source

Immunomodulatory effects of atorvastatin on MRL/lpr mice

Advances in Rheumatology, 2022
Background Statins have long been extensively prescribed as effective lipid-lowering agents, but statins have also been recognized as novel immunomodulators in recent years.
Jing Sun, Weidong Xu, Zhiying Wu, Caijin Cao, Yane Tan, Meifang Zhu, Hongze Wu, Jianping Yu   +7 more
doaj   +1 more source

Atorvastatin suppresses lipopolysaccharide-induced inflammation in human coronary artery endothelial cells

Brazilian Journal of Pharmaceutical Sciences, 2022
The present study was designed to examine the effects of atorvastatin on vascular inflammatory responses in human coronary artery endothelial cells(HCAECs), when challenged by lipopolysaccharide (LPS), a Toll-like receptor-4 (TLR4) ligand.
Zhen Tian, Zhitao Li, Tian Guo, He Li, Yanshuang Mu   +4 more
doaj   +1 more source